Company Description Abeona was founded in March 2013 to develop therapies for patients with lysosomal storage diseases. Abeona has exclusive rights to develop it’s two lead products, ABX-A and ABX-B, for Sanfilippo syndrome based on therapies developed by scientists at Nationwide Children’s Hospital.
Proceeds Purposes The support from multiple international foundations with a mandate for identifying lead Sanfilippo therapies enables us to complete preclinical development and sets the stage to enter clinical trials in 2014.
M&A Terms
Venture Investor Children’s Medical & Research Foundation